Literature DB >> 25863795

Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE.

Zhijun Wang1, Julius Chapiro2, Rüdiger Schernthaner2, Rafael Duran2, Rongxin Chen2, Jean-François Geschwind3, MingDe Lin4.   

Abstract

RATIONALE AND
OBJECTIVES: To validate the concordance of a semiautomated multimodality lesion segmentation technique between contrast-enhanced magnetic resonance imaging (CE-MRI), cone-beam computed tomography (CBCT), and multidetector CT (MDCT) in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).
MATERIALS AND METHODS: This retrospective analysis included 45 patients with unresectable HCC who underwent baseline CE-MRI within 1 month before the treatment, intraprocedural CBCT during conventional TACE, and MDCT within 24 hours after TACE. Fourteen patients were excluded because of atypical lesion morphology, portal vein invasion, or small lesion size which precluded sufficient lesion visualization. Thirty-one patients with a total of 40 target lesions were included into the analysis. A tumor segmentation software, based on non-Euclidean geometry and theory of radial basis functions, was used to allow for the segmentation of target lesions in 3D on all three modalities. The algorithm created image-based masks located in a 3D region whose center and size were defined by the user, yielding the nomenclature "semiautomatic". On the basis of that, tumor volumes on all three modalities were calculated and compared using a linear regression model (R(2) values). Residual plots were used to analyze drift and variance of the values.
RESULTS: The mean value of tumor volumes was 18.72 ± 19.13 cm(3) (range, 0.41-59.16 cm(3)) on CE-MRI, 21.26 ± 21.99 cm(3) (range, 0.62-86.82 cm(3)) on CBCT, and 19.88 ± 20.88 cm(3) (range, 0.45-75.24 cm(3)) on MDCT. The average volumes of the tumor were not significantly different between CE-MRI and DP-CBCT, DP-CBCT and MDCT, MDCT and CE-MRI (P = .577, .770, and .794, respectively). A strong correlation between volumes on CE-MRI and CBCT, CBCT and MDCT, MDCT and CE-MRI was observed (R(2) = 0.974, 0.992 and 0.983, respectively). When plotting the residuals, no drift was observed for all methods showing deviations of no >10% of absolute volumes (in cm(3)).
CONCLUSIONS: A semiautomated 3D segmentation of HCC lesions treated with TACE provides high volumetric concordance across all tested imaging modalities.
Copyright © 2015 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-arm cone-beam CT; MDCT; MRI; TACE; Tumor segmentation; hepatocellular carcinoma

Mesh:

Substances:

Year:  2015        PMID: 25863795      PMCID: PMC4464945          DOI: 10.1016/j.acra.2015.03.001

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  20 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Shape-constraint region growing for delineation of hepatic metastases on contrast-enhanced computed tomograph scans.

Authors:  Binsheng Zhao; Lawrence H Schwartz; Li Jiang; Jane Colville; Chaya Moskowitz; Liang Wang; Robert Leftowitz; Fan Liu; John Kalaigian
Journal:  Invest Radiol       Date:  2006-10       Impact factor: 6.016

3.  Volumetric analysis of liver metastases in computed tomography with the fuzzy C-means algorithm.

Authors:  Peter J Yim; Amit V Vora; Deepak Raghavan; Ravi Prasad; Matthew McAullife; Pamela Ohman-Strickland; John L Nosher
Journal:  J Comput Assist Tomogr       Date:  2006 Mar-Apr       Impact factor: 1.826

4.  Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

Authors:  Ihab R Kamel; Eleni Liapi; Diane K Reyes; Marianna Zahurak; David A Bluemke; Jean-François H Geschwind
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

5.  CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.

Authors:  S A Sohaib; B Turner; J A Hanson; M Farquharson; R T Oliver; R H Reznek
Journal:  Br J Radiol       Date:  2000-11       Impact factor: 3.039

Review 6.  Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.

Authors:  Julius Chapiro; MingDe Lin; Rafael Duran; Rüdiger E Schernthaner; Jean-François Geschwind
Journal:  Expert Rev Anticancer Ther       Date:  2014-11-05       Impact factor: 4.512

7.  Comparison of two-dimensional and three-dimensional iterative watershed segmentation methods in hepatic tumor volumetrics.

Authors:  Shonket Ray; Rosalie Hagge; Marijo Gillen; Miguel Cerejo; Shidrokh Shakeri; Laurel Beckett; Tamara Greasby; Ramsey D Badawi
Journal:  Med Phys       Date:  2008-12       Impact factor: 4.071

Review 8.  Assessment of tumor response on MR imaging after locoregional therapy.

Authors:  Josephina A Vossen; Manon Buijs; Ihab R Kamel
Journal:  Tech Vasc Interv Radiol       Date:  2006-09

Review 9.  Assessment of liver tumor response to therapy: role of quantitative imaging.

Authors:  Fernanda D Gonzalez-Guindalini; Marcos P F Botelho; Carla B Harmath; Kumaresan Sandrasegaran; Frank H Miller; Riad Salem; Vahid Yaghmai
Journal:  Radiographics       Date:  2013-10       Impact factor: 5.333

10.  Comparing the detectability of hepatocellular carcinoma by C-arm dual-phase cone-beam computed tomography during hepatic arteriography with conventional contrast-enhanced magnetic resonance imaging.

Authors:  Romaric Loffroy; MingDe Lin; Pramod Rao; Nikhil Bhagat; Niels Noordhoek; Alessandro Radaelli; Järl Blijd; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2011-02-17       Impact factor: 2.797

View more
  10 in total

1.  Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?

Authors:  Yan Zhao; Rafael Duran; Wei Bai; Sonia Sahu; Wenjun Wang; Sven Kabus; MingDe Lin; Guohong Han; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2017-10-30       Impact factor: 2.740

2.  The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma.

Authors:  Susanne Smolka; Julius Chapiro; Wilfred Manzano; John Treilhard; Eric Reiner; Yanhong Deng; Yan Zhao; Bernd Hamm; James S Duncan; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind
Journal:  Clin Imaging       Date:  2017-06-07       Impact factor: 1.605

Review 3.  Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities.

Authors:  Chrysanthos D Christou; Georgios Tsoulfas
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

4.  3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.

Authors:  Florian N Fleckenstein; Rüdiger E Schernthaner; Rafael Duran; Jae Ho Sohn; Sonia Sahu; Yan Zhao; Bernd Hamm; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind; Julius Chapiro
Journal:  Eur Radiol       Date:  2016-01-13       Impact factor: 5.315

5.  Paraplegia after transcatheter artery chemoembolization in a child with clear cell sarcoma of the kidney: A case report.

Authors:  Jia-Bin Cai; Min He; Fa-Liang Wang; Jie-Ni Xiong; Jun-Qing Mao; Zhong-Hai Guan; Lin-Jie Li; Jin-Hu Wang
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

6.  Assessment of the feasibility of TACE combined with intratumoral injection of cisplatin in hepatocellular carcinoma.

Authors:  Song Zhaomin; Liu Zifeng; Yin Chenghui; Yang Jiali; Peng Xun; Zhao Peili; Lang Xiaolin
Journal:  Open Med (Wars)       Date:  2015-12-17

7.  Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases.

Authors:  Chihua Fang; Jihyun An; Antonio Bruno; Xiujun Cai; Jia Fan; Jiro Fujimoto; Rita Golfieri; Xishan Hao; Hongchi Jiang; Long R Jiao; Anand V Kulkarni; Hauke Lang; Cosmas Rinaldi A Lesmana; Qiang Li; Lianxin Liu; Yingbin Liu; Wanyee Lau; Qiping Lu; Kwan Man; Hitoshi Maruyama; Cristina Mosconi; Necati Örmeci; Michael Pavlides; Guilherme Rezende; Joo Hyun Sohn; Sombat Treeprasertsuk; Valérie Vilgrain; Hao Wen; Sai Wen; Xianyao Quan; Rafael Ximenes; Yinmo Yang; Bixiang Zhang; Weiqi Zhang; Peng Zhang; Shaoxiang Zhang; Xiaolong Qi
Journal:  Hepatol Int       Date:  2020-07-07       Impact factor: 6.047

8.  Using Routinely Collected Health Records to Identify the Fine-Resolution Spatial Patterns of Soil-Transmitted Helminth Infections in Rwanda.

Authors:  Elias Nyandwi; Tom Veldkamp; Sherif Amer; Eugene Ruberanziza; Nadine Rujeni; Ireneé Umulisa
Journal:  Trop Med Infect Dis       Date:  2022-08-22

9.  Schistosomiasis mansoni incidence data in Rwanda can improve prevalence assessments, by providing high-resolution hotspot and risk factors identification.

Authors:  E Nyandwi; A Veldkamp; S Amer; C Karema; I Umulisa
Journal:  BMC Public Health       Date:  2017-10-25       Impact factor: 3.295

10.  Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment.

Authors:  Şükran Alpdemir; Tayfun Vural; Göknur Kara; Cem Bayram; Erdem Haberal; Emir Baki Denkbaş
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.